KR101822902B1 - 뉴클레아제-매개 dna 조립 - Google Patents

뉴클레아제-매개 dna 조립 Download PDF

Info

Publication number
KR101822902B1
KR101822902B1 KR1020177001792A KR20177001792A KR101822902B1 KR 101822902 B1 KR101822902 B1 KR 101822902B1 KR 1020177001792 A KR1020177001792 A KR 1020177001792A KR 20177001792 A KR20177001792 A KR 20177001792A KR 101822902 B1 KR101822902 B1 KR 101822902B1
Authority
KR
South Korea
Prior art keywords
nucleic acid
sequence
dna
complementary
degraded
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177001792A
Other languages
English (en)
Korean (ko)
Other versions
KR20170020505A (ko
Inventor
크리스 쇤헤르
존 맥훠터
코레이 모몬트
린 맥도날드
앤드류 제이. 머피
그렉 에스. 워쇼
호세 에프. 로하스
카-만 비너스 라이
데이비드 엠. 발렌주엘라
케이틀린 몬타냐
Original Assignee
리제너론 파마슈티칼스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리제너론 파마슈티칼스 인코포레이티드 filed Critical 리제너론 파마슈티칼스 인코포레이티드
Publication of KR20170020505A publication Critical patent/KR20170020505A/ko
Application granted granted Critical
Publication of KR101822902B1 publication Critical patent/KR101822902B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C12N15/1031—Mutagenizing nucleic acids mutagenesis by gene assembly, e.g. assembly by oligonucleotide extension PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020177001792A 2014-06-23 2015-06-23 뉴클레아제-매개 dna 조립 Active KR101822902B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462015809P 2014-06-23 2014-06-23
US62/015,809 2014-06-23
US201462016400P 2014-06-24 2014-06-24
US62/016,400 2014-06-24
US201462036983P 2014-08-13 2014-08-13
US62/036,983 2014-08-13
PCT/US2015/037199 WO2015200334A1 (en) 2014-06-23 2015-06-23 Nuclease-mediated dna assembly

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020187002009A Division KR102237151B1 (ko) 2014-06-23 2015-06-23 뉴클레아제-매개 dna 조립

Publications (2)

Publication Number Publication Date
KR20170020505A KR20170020505A (ko) 2017-02-22
KR101822902B1 true KR101822902B1 (ko) 2018-01-30

Family

ID=53525285

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177001792A Active KR101822902B1 (ko) 2014-06-23 2015-06-23 뉴클레아제-매개 dna 조립
KR1020187002009A Active KR102237151B1 (ko) 2014-06-23 2015-06-23 뉴클레아제-매개 dna 조립

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187002009A Active KR102237151B1 (ko) 2014-06-23 2015-06-23 뉴클레아제-매개 dna 조립

Country Status (25)

Country Link
US (6) US9738897B2 (https=)
EP (3) EP3708663A1 (https=)
JP (4) JP6336140B2 (https=)
KR (2) KR101822902B1 (https=)
CN (2) CN112029787B (https=)
AU (3) AU2015280120B2 (https=)
BR (1) BR112016030145A8 (https=)
CA (1) CA2953499C (https=)
CY (2) CY1120520T1 (https=)
DK (2) DK3155099T3 (https=)
ES (2) ES2781323T3 (https=)
HR (1) HRP20200523T1 (https=)
HU (1) HUE049405T2 (https=)
IL (1) IL249612B (https=)
LT (1) LT3354732T (https=)
MX (2) MX384887B (https=)
NZ (1) NZ765591A (https=)
PL (2) PL3354732T3 (https=)
PT (2) PT3155099T (https=)
RS (1) RS60366B1 (https=)
RU (1) RU2707911C2 (https=)
SG (2) SG10201803444YA (https=)
SI (1) SI3354732T1 (https=)
SM (1) SMT202000174T1 (https=)
WO (1) WO2015200334A1 (https=)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
ES2781323T3 (es) 2014-06-23 2020-09-01 Regeneron Pharma Montaje de ADN mediado por nucleasas
US20170198268A1 (en) * 2014-07-09 2017-07-13 Gen9, Inc. Compositions and Methods for Site-Directed DNA Nicking and Cleaving
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
CA2969619A1 (en) 2014-12-03 2016-06-09 Agilent Technologies, Inc. Guide rna with chemical modifications
WO2016109255A1 (en) * 2014-12-30 2016-07-07 University Of South Florida Methods and compositions for cloning into large vectors
KR102888521B1 (ko) 2015-04-06 2025-11-19 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Crispr/cas-매개 유전자 조절을 위한 화학적으로 변형된 가이드 rna
AU2016270587B2 (en) 2015-05-29 2020-12-24 Regeneron Pharmaceuticals, Inc. Non-human animals having a disruption in a C9ORF72 locus
IL310721B2 (en) 2015-10-23 2025-11-01 Harvard College Nucleobase editors and uses thereof
US11208649B2 (en) 2015-12-07 2021-12-28 Zymergen Inc. HTP genomic engineering platform
BR112018011503A2 (pt) 2015-12-07 2018-12-04 Zymergen Inc promotores da corynebacterium glutamicum
US9988624B2 (en) 2015-12-07 2018-06-05 Zymergen Inc. Microbial strain improvement by a HTP genomic engineering platform
KR20230006929A (ko) 2016-01-13 2023-01-11 리제너론 파마슈티칼스 인코포레이티드 조작된 중쇄 다양성 영역을 갖는 설치류
KR102483193B1 (ko) 2016-06-03 2023-01-04 리제너론 파마슈티칼스 인코포레이티드 외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
EP3478845A4 (en) 2016-06-30 2019-07-31 Zymergen, Inc. METHOD OF GENERATING A GLUCOSE PERMEASE LIBRARY AND USES THEREOF
US10544390B2 (en) 2016-06-30 2020-01-28 Zymergen Inc. Methods for generating a bacterial hemoglobin library and uses thereof
US20190330659A1 (en) * 2016-07-15 2019-10-31 Zymergen Inc. Scarless dna assembly and genome editing using crispr/cpf1 and dna ligase
JP2019523009A (ja) 2016-07-29 2019-08-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｃ末端切断型フィブリリン−１の発現をもたらす変異を有するマウス
CN110214183A (zh) 2016-08-03 2019-09-06 哈佛大学的校长及成员们 腺苷核碱基编辑器及其用途
WO2018031683A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US20180105806A1 (en) * 2016-09-07 2018-04-19 Massachusetts Institute Of Technology Method for rna-guided endonuclease-based dna assembly
US10704082B2 (en) 2016-09-15 2020-07-07 ArcherDX, Inc. Methods of nucleic acid sample preparation
WO2018053365A1 (en) 2016-09-15 2018-03-22 ArcherDX, Inc. Methods of nucleic acid sample preparation for analysis of cell-free dna
CN109862785B (zh) 2016-09-30 2022-09-06 瑞泽恩制药公司 C9orf72基因座中具有六核苷酸重复扩增的非人类动物
KR102622411B1 (ko) 2016-10-14 2024-01-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
ES2940620T3 (es) * 2016-11-02 2023-05-09 Archerdx Llc Métodos de preparación de muestras de ácido nucleico para la secuenciación del repertorio inmunitario
SG10201913483XA (en) 2016-11-04 2020-03-30 Regeneron Pharma Non-human animals having an engineered immunoglobulin lambda light chain locus
SG10202106058WA (en) * 2016-12-08 2021-07-29 Intellia Therapeutics Inc Modified guide rnas
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
JP2020507312A (ja) * 2017-02-10 2020-03-12 ザイマージェン インコーポレイテッド 複数の宿主用の複数のｄｎａコンストラクトのアセンブリ及び編集のためのモジュラーユニバーサルプラスミド設計戦略
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
US12390514B2 (en) 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
KR20240116572A (ko) 2017-03-23 2024-07-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US20180346963A1 (en) * 2017-06-01 2018-12-06 Counsyl, Inc. Preparation of Concatenated Polynucleotides
WO2018231872A1 (en) * 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
US10081829B1 (en) * 2017-06-13 2018-09-25 Genetics Research, Llc Detection of targeted sequence regions
CN111094573A (zh) 2017-07-12 2020-05-01 梅约医学教育与研究基金会 有效靶向敲入或基因置换的材料和方法
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
CN110891420B (zh) 2017-07-31 2022-06-03 瑞泽恩制药公司 Cas转基因小鼠胚胎干细胞和小鼠及其应用
KR20200033259A (ko) 2017-07-31 2020-03-27 리제너론 파마슈티칼스 인코포레이티드 생체내에서 CRISPR/Cas-매개된 파괴 또는 삭제 및 외인성 도너 핵산과의 CRISPR/Cas-유도된 재조합을 평가하기 위한 방법 및 조성물
WO2019039417A1 (ja) * 2017-08-21 2019-02-28 国立大学法人徳島大学 ヌクレオチド標的認識を利用した標的配列特異的改変技術
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
EP3678680A4 (en) 2017-09-05 2021-12-01 Regeneron Pharmaceuticals, Inc. ADMINISTRATION OF A GENE EDITING SYSTEM CONTAINING A SINGLE RETROVIRAL PARTICLE AND METHODS OF GENERATION AND USE
US20190098879A1 (en) 2017-09-29 2019-04-04 Regeneron Pharmaceuticals, Inc. Non-Human Animals Comprising A Humanized TTR Locus And Methods Of Use
KR20250107288A (ko) 2017-10-16 2025-07-11 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
JP7361031B2 (ja) * 2017-11-30 2023-10-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物
HUE060608T2 (hu) 2017-12-05 2023-03-28 Regeneron Pharma Genetikailag módosított immunglobulin lambda könnyûlánccal rendelkezõ egerek és azok alkalmazása
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
EP3592140A1 (en) 2018-03-19 2020-01-15 Regeneron Pharmaceuticals, Inc. Transcription modulation in animals using crispr/cas systems
IL314733A (en) 2018-03-26 2024-10-01 Regeneron Pharma Humanized rodents for testing therapeutic agents
WO2019204531A1 (en) * 2018-04-18 2019-10-24 Ligandal, Inc. Methods and compositions for genome editing
WO2019217785A1 (en) 2018-05-10 2019-11-14 St. Jude Children's Research Hospital, Inc. High-throughput method for characterizing the genome-wide activity of editing nucleases in vitro
WO2019213910A1 (en) * 2018-05-10 2019-11-14 Syngenta Participations Ag Methods and compositions for targeted editing of polynucleotides
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
CA3107002A1 (en) * 2018-08-15 2020-04-30 Zymergen Inc. Applications of crispri in high throughput metabolic engineering
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
KR102925054B1 (ko) 2018-12-20 2026-02-10 리제너론 파마슈티칼스 인코포레이티드 뉴클레아제-매개 반복부 팽창
EP3908291A4 (en) 2019-01-07 2023-01-11 Dana-Farber Cancer Institute, Inc. SMALL MOLECULAR DEGRADERS OF FKBP12 VIA RECRUITMENT OF THE VON HIPPEL-LINDAU E3 UBIQUITIN LIGASE (VHL) AND USE IN DTAG SYSTEMS
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020191233A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
KR102661779B1 (ko) 2019-04-04 2024-04-30 리제너론 파마슈티칼스 인코포레이티드 인간화 응고 인자 12 좌위를 포함하는 비-인간 동물
RU2771374C1 (ru) * 2019-04-04 2022-05-04 Редженерон Фармасьютикалс, Инк. Способы для бесшовного внесения целевых модификаций в направленные векторы
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
GB201905651D0 (en) * 2019-04-24 2019-06-05 Lightbio Ltd Nucleic acid constructs and methods for their manufacture
WO2020224987A1 (en) * 2019-05-06 2020-11-12 Dsm Ip Assets B.V. Multipartite crispr donor
US11891618B2 (en) 2019-06-04 2024-02-06 Regeneron Pharmaceuticals, Inc. Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use
MX2021014893A (es) 2019-06-05 2022-03-11 Regeneron Pharma Animales no humanos que tienen un repertorio de cadena ligera lambda limitado expresado a partir del locus kappa y usos de estos.
MX2021015122A (es) 2019-06-07 2022-04-06 Regeneron Pharma Animales no humanos que comprenden un locus de albumina humanizado.
CN114630910A (zh) 2019-06-25 2022-06-14 伊纳瑞农业技术有限公司 改善的同源依赖修复基因组编辑
CN112175939A (zh) * 2019-07-03 2021-01-05 华大青兰生物科技(无锡)有限公司 一种基于同源序列的核酸拼接方法及其应用
GB201913898D0 (en) * 2019-09-26 2019-11-13 Lightbio Ltd Nucleic acid construct
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
WO2021108363A1 (en) 2019-11-25 2021-06-03 Regeneron Pharmaceuticals, Inc. Crispr/cas-mediated upregulation of humanized ttr allele
CN115335521B (zh) * 2019-11-27 2026-04-28 克里斯珀医疗股份公司 合成rna分子的方法
EP4085145A4 (en) * 2019-12-30 2024-02-21 The Broad Institute Inc. Guided excision-transposition systems
WO2021154791A1 (en) 2020-01-28 2021-08-05 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized pnpla3 locus and methods of use
EP4099821A1 (en) 2020-02-07 2022-12-14 Regeneron Pharmaceuticals, Inc. <smallcaps/>? ? ?klkb1? ? ? ? ?non-human animals comprising a humanizedlocus and methods of use
CN111334523A (zh) * 2020-03-13 2020-06-26 天津大学 一种大尺度dna的体内多轮迭代组装方法
US20230102342A1 (en) 2020-03-23 2023-03-30 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
IL297761A (en) 2020-05-08 2022-12-01 Broad Inst Inc Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence
CA3165366A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
WO2022187125A1 (en) * 2021-03-01 2022-09-09 The Regents Of The University Of California Methods for generating a crispr array
JP2024534945A (ja) 2021-09-10 2024-09-26 アジレント・テクノロジーズ・インク 化学修飾を有するプライム編集のためのガイドｒｎａ
CN113782103B (zh) * 2021-10-26 2024-07-09 大连大学 一种基于组合式酶切机制的dna矩阵处理方法
US20240415980A1 (en) 2021-10-28 2024-12-19 Regeneron Pharmaceuticals, Inc. Crispr/cas-related methods and compositions for knocking out c5
KR20240117571A (ko) 2021-12-08 2024-08-01 리제너론 파마슈티칼스 인코포레이티드 돌연변이 마이오실린 질환 모델 및 이의 용도
WO2023147547A1 (en) * 2022-01-31 2023-08-03 Integrated Dna Technologies, Inc. Recombination-based dna assembly methods and compositions
WO2023150798A1 (en) 2022-02-07 2023-08-10 Regeneron Pharmaceuticals, Inc. Compositions and methods for defining optimal treatment timeframes in lysosomal disease
AU2023218391A1 (en) 2022-02-11 2024-07-11 Regeneron Pharmaceuticals, Inc. Compositions and methods for screening 4r tau targeting agents
WO2023235725A2 (en) 2022-05-31 2023-12-07 Regeneron Pharmaceuticals, Inc. Crispr-based therapeutics for c9orf72 repeat expansion disease
EP4593590A1 (en) 2022-09-29 2025-08-06 Regeneron Pharmaceuticals, Inc. Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes
KR20260040036A (ko) * 2023-07-12 2026-03-23 바이오스파이더 테크놀로지스, 인코퍼레이티드 핵산을 함유하는 샘플의 처리
CN117904069B (zh) * 2024-01-04 2025-07-15 华中农业大学 VirEN蛋白介导的DNA拼接和基因编辑方法
CN117987436B (zh) * 2024-04-03 2024-06-25 南京鸿明生物科技有限公司 一种双链靶dna序列的制备方法
WO2025250495A1 (en) 2024-05-28 2025-12-04 Regeneron Pharmaceuticals, Inc. Acceleration of human hepatocyte engraftment in humanized liver animals by supplementing paracrine ligands or agonists that activate human liver regeneration signals

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100035768A1 (en) 2008-02-15 2010-02-11 Gibson Daniel G Methods for in vitro joining and combinatorial assembly of nucleic acid molecules

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312892B1 (en) 1996-07-19 2001-11-06 Cornell Research Foundation, Inc. High fidelity detection of nucleic acid differences by ligase detection reaction
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US20030104526A1 (en) 1999-03-24 2003-06-05 Qiang Liu Position dependent recognition of GNN nucleotide triplets by zinc fingers
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
AU2002228841C1 (en) 2000-12-07 2006-11-23 Sangamo Biosciences, Inc Regulation of angiogenesis with zinc finger proteins
AU2002225187A1 (en) 2001-01-22 2002-07-30 Sangamo Biosciences, Inc. Zinc finger polypeptides and their use
WO2002057293A2 (en) 2001-01-22 2002-07-25 Sangamo Biosciences, Inc. Modified zinc finger binding proteins
WO2003087341A2 (en) 2002-01-23 2003-10-23 The University Of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
AU2003215869B2 (en) 2002-03-15 2008-04-24 Cellectis Hybrid and single chain meganucleases and use thereof
WO2003080809A2 (en) 2002-03-21 2003-10-02 Sangamo Biosciences, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
EP2806025B1 (en) 2002-09-05 2019-04-03 California Institute of Technology Use of zinc finger nucleases to stimulate gene targeting
AU2003290518A1 (en) 2002-09-06 2004-04-23 Fred Hutchinson Cancer Research Center Methods and compositions concerning designed highly-specific nucleic acid binding proteins
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
EP1591521A1 (en) 2004-04-30 2005-11-02 Cellectis I-Dmo I derivatives with enhanced activity at 37 degrees C and use thereof
AU2005287278B2 (en) 2004-09-16 2011-08-04 Sangamo Biosciences, Inc. Compositions and methods for protein production
EP1863909B2 (en) 2005-03-15 2014-09-10 Cellectis I-crei meganuclease variants with modified specificity, method of preparation and uses thereof
WO2006097784A1 (en) 2005-03-15 2006-09-21 Cellectis I-crei meganuclease variants with modified specificity, method of preparation and uses thereof
ES2586210T3 (es) 2006-12-14 2016-10-13 Sangamo Biosciences, Inc. Proteínas de dedo de zinc no canónicas optimizadas
EP2206723A1 (en) 2009-01-12 2010-07-14 Bonas, Ulla Modular DNA-binding domains
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
EP2408921B1 (en) 2009-03-20 2017-04-19 Sangamo BioSciences, Inc. Modification of cxcr4 using engineered zinc finger proteins
US8772008B2 (en) 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
WO2011017293A2 (en) 2009-08-03 2011-02-10 The General Hospital Corporation Engineering of zinc finger arrays by context-dependent assembly
US8518392B2 (en) 2009-08-14 2013-08-27 Regeneron Pharmaceuticals, Inc. Promoter-regulated differentiation-dependent self-deleting cassette
CA2779858C (en) 2009-10-29 2019-10-29 Regeneron Pharmaceuticals, Inc. Multifunctional alleles
WO2011072246A2 (en) 2009-12-10 2011-06-16 Regents Of The University Of Minnesota Tal effector-mediated dna modification
WO2011101696A1 (en) * 2010-02-18 2011-08-25 Cellectis Improved meganuclease recombination system
GB201009732D0 (en) 2010-06-10 2010-07-21 Gene Bridges Gmbh Direct cloning
WO2012051327A2 (en) 2010-10-12 2012-04-19 Cornell University Method of dual-adapter recombination for efficient concatenation of multiple dna fragments in shuffled or specified arrangements
US9637739B2 (en) * 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
WO2013141680A1 (en) 2012-03-20 2013-09-26 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
AU2013335451C1 (en) 2012-10-23 2024-07-04 Toolgen Incorporated Composition for cleaving a target DNA comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof
PL3360964T3 (pl) 2012-12-06 2020-03-31 Sigma-Aldrich Co. Llc Modyfikacja i regulacja genomu oparta na crispr
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
EP3031921B1 (en) * 2012-12-12 2025-03-12 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
DK2931891T3 (da) 2012-12-17 2019-08-19 Harvard College Rna-styret modificering af menneskelige genomer
EP2922393B2 (en) 2013-02-27 2022-12-28 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Gene editing in the oocyte by cas9 nucleases
WO2014143381A1 (en) 2013-03-09 2014-09-18 Agilent Technologies, Inc. Methods of in vivo engineering of large sequences using multiple crispr/cas selections of recombineering events
EP4286517A3 (en) 2013-04-04 2024-03-13 President and Fellows of Harvard College Therapeutic uses of genome editing with crispr/cas systems
US10421957B2 (en) 2013-07-29 2019-09-24 Agilent Technologies, Inc. DNA assembly using an RNA-programmable nickase
EP3988649B1 (en) 2013-09-18 2024-11-27 Kymab Limited Methods, cells and organisms
EP3083958B1 (en) 2013-12-19 2019-04-17 Amyris, Inc. Methods for genomic integration
US9850525B2 (en) 2014-01-29 2017-12-26 Agilent Technologies, Inc. CAS9-based isothermal method of detection of specific DNA sequence
JP2016006930A (ja) 2014-06-20 2016-01-14 ソニー株式会社 撮像装置および撮像方法
ES2781323T3 (es) 2014-06-23 2020-09-01 Regeneron Pharma Montaje de ADN mediado por nucleasas
US20170198268A1 (en) 2014-07-09 2017-07-13 Gen9, Inc. Compositions and Methods for Site-Directed DNA Nicking and Cleaving
US20160053272A1 (en) 2014-07-18 2016-02-25 Whitehead Institute For Biomedical Research Methods Of Modifying A Sequence Using CRISPR
WO2016025759A1 (en) 2014-08-14 2016-02-18 Shen Yuelei Dna knock-in system
WO2016033115A1 (en) 2014-08-25 2016-03-03 Curza Global, Llc Method of producing n-alkyl polyamines
EP3778891A1 (en) 2014-08-27 2021-02-17 New England Biolabs, Inc. Synthon formation
CN104357438B (zh) * 2014-09-23 2020-04-24 中国科学院天津工业生物技术研究所 一种dna组装和克隆的方法
CN113215115B (zh) 2014-12-16 2024-07-02 C3J治疗公司 用于体外病毒基因组工程的组合物和方法
WO2016109255A1 (en) 2014-12-30 2016-07-07 University Of South Florida Methods and compositions for cloning into large vectors
WO2016130697A1 (en) 2015-02-11 2016-08-18 Memorial Sloan Kettering Cancer Center Methods and kits for generating vectors that co-express multiple target molecules
US20190330659A1 (en) 2016-07-15 2019-10-31 Zymergen Inc. Scarless dna assembly and genome editing using crispr/cpf1 and dna ligase
US20180105806A1 (en) 2016-09-07 2018-04-19 Massachusetts Institute Of Technology Method for rna-guided endonuclease-based dna assembly

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100035768A1 (en) 2008-02-15 2010-02-11 Gibson Daniel G Methods for in vitro joining and combinatorial assembly of nucleic acid molecules
JP2011512140A (ja) 2008-02-15 2011-04-21 シンセティック ジェノミクス インコーポレーテッド 核酸分子のインビトロでの連結および組み合わせアセンブリのための方法

Also Published As

Publication number Publication date
EP3354732B1 (en) 2020-01-08
RU2017101329A3 (https=) 2019-02-15
JP2020120662A (ja) 2020-08-13
SI3354732T1 (sl) 2020-07-31
ES2666179T3 (es) 2018-05-03
JP2017113031A (ja) 2017-06-29
NZ727952A (en) 2021-11-26
EP3354732A1 (en) 2018-08-01
PT3354732T (pt) 2020-04-02
NZ765591A (en) 2022-09-30
MX2016016905A (es) 2017-08-10
EP3155099A1 (en) 2017-04-19
US20150376628A1 (en) 2015-12-31
CA2953499C (en) 2023-10-24
AU2015280120B2 (en) 2017-05-25
KR20180011858A (ko) 2018-02-02
AU2017213564A1 (en) 2017-08-31
US9738897B2 (en) 2017-08-22
PL3155099T3 (pl) 2018-08-31
WO2015200334A1 (en) 2015-12-30
MX379237B (es) 2025-03-10
WO2015200334A4 (en) 2016-03-17
RU2707911C2 (ru) 2019-12-02
LT3354732T (lt) 2020-04-10
US20190194668A1 (en) 2019-06-27
DK3155099T3 (en) 2018-05-07
AU2015280120A1 (en) 2017-01-19
JP6336140B2 (ja) 2018-06-06
EP3155099B1 (en) 2018-03-21
JP6684241B2 (ja) 2020-04-22
RU2017101329A (ru) 2018-07-24
HK1256688A1 (en) 2019-10-04
US20160115486A1 (en) 2016-04-28
CA2953499A1 (en) 2015-12-30
SG11201610481YA (en) 2017-01-27
CY1120520T1 (el) 2019-07-10
CN112029787B (zh) 2024-07-19
KR20170020505A (ko) 2017-02-22
CY1122962T1 (el) 2021-10-29
BR112016030145A2 (pt) 2018-02-20
AU2019200094B2 (en) 2021-06-24
MX384887B (es) 2025-03-14
RS60366B1 (sr) 2020-07-31
PT3155099T (pt) 2018-04-20
HUE049405T2 (hu) 2020-09-28
JP2020202836A (ja) 2020-12-24
US10626402B2 (en) 2020-04-21
JP7058306B2 (ja) 2022-04-21
US9580715B2 (en) 2017-02-28
US20180002708A1 (en) 2018-01-04
CN106715694B (zh) 2020-10-20
US10273488B2 (en) 2019-04-30
HRP20200523T1 (hr) 2020-08-07
CN106715694A (zh) 2017-05-24
IL249612A0 (en) 2017-02-28
JP6737974B1 (ja) 2020-08-12
SMT202000174T1 (it) 2020-05-08
KR102237151B1 (ko) 2021-04-07
AU2017213564B2 (en) 2018-10-18
JP2017518757A (ja) 2017-07-13
US11932859B2 (en) 2024-03-19
PL3354732T3 (pl) 2020-06-15
IL249612B (en) 2021-04-29
US20200208161A1 (en) 2020-07-02
ES2781323T3 (es) 2020-09-01
MX2021000857A (es) 2021-07-28
EP3708663A1 (en) 2020-09-16
US20240229048A1 (en) 2024-07-11
AU2019200094A1 (en) 2019-01-31
CN112029787A (zh) 2020-12-04
DK3354732T3 (da) 2020-04-06
SG10201803444YA (en) 2018-06-28
BR112016030145A8 (pt) 2018-12-11

Similar Documents

Publication Publication Date Title
KR101822902B1 (ko) 뉴클레아제-매개 dna 조립
HK40035694A (en) Nuclease-mediated dna assembly
HK1256688B (en) Nuclease-mediated dna assembly
HK1235816B (en) Nuclease-mediated dna assembly
HK1235816A1 (en) Nuclease-mediated dna assembly
NZ727952B2 (en) Nuclease-mediated dna assembly

Legal Events

Date Code Title Description
A201 Request for examination
A302 Request for accelerated examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 9